KARO BIO ACQUIRES OVER 90 PER CENT OF MEDCORE

Karo Bio AB (publ) acquires more than 90 percent of the shares in MedCore AB.MedCore markets primarily licensed medtech products to pharmacies and hospitals in the Nordic region. The products target the therapeutic areas Diabetes, Anesthesia/Intensive Care and Surgery. Turnover is approx. MSEK 50 with an operating profit expected to be slightly positive in 2015. The purchase price is MSEK 18. In a first round, Karo Bio pays slightly more than 16 MSEK in new shares for a little more than 90 per cent of the shares in MedCore. Shareholders representing more than 90 per cent of the shares